| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Neoplasms, Second Primary | 3 | 2019 | 100 | 1.05 | Why? |
| Mitral Valve Insufficiency | 2 | 2018 | 302 | 0.72 | Why? |
| Sports Medicine | 1 | 2021 | 237 | 0.67 | Why? |
| Drug Users | 1 | 2019 | 234 | 0.62 | Why? |
| Death, Sudden, Cardiac | 1 | 2021 | 522 | 0.60 | Why? |
| Return to Sport | 1 | 2021 | 456 | 0.59 | Why? |
| Substance Abuse, Intravenous | 1 | 2019 | 411 | 0.56 | Why? |
| Mitral Valve | 1 | 2018 | 342 | 0.54 | Why? |
| Endocarditis | 1 | 2019 | 368 | 0.53 | Why? |
| Cardiovascular Agents | 1 | 2018 | 663 | 0.45 | Why? |
| Ventricular Function, Left | 1 | 2018 | 1555 | 0.37 | Why? |
| Bone Marrow Neoplasms | 1 | 2018 | 60 | 0.36 | Why? |
| Cardiac Valve Annuloplasty | 1 | 2017 | 20 | 0.36 | Why? |
| Lymphoma, Non-Hodgkin | 2 | 2019 | 403 | 0.36 | Why? |
| Hexokinase | 1 | 2017 | 10 | 0.35 | Why? |
| Stroke Volume | 1 | 2018 | 2153 | 0.35 | Why? |
| Fenofibrate | 1 | 2017 | 22 | 0.34 | Why? |
| Tricuspid Valve Insufficiency | 1 | 2018 | 94 | 0.34 | Why? |
| Immunoglobulin Light-chain Amyloidosis | 1 | 2017 | 94 | 0.32 | Why? |
| Cardiovascular Diseases | 8 | 2021 | 11497 | 0.32 | Why? |
| Device Removal | 1 | 2018 | 221 | 0.31 | Why? |
| Aortic Valve Insufficiency | 1 | 2017 | 136 | 0.31 | Why? |
| Aspirin | 3 | 2018 | 1043 | 0.31 | Why? |
| American Heart Association | 3 | 2021 | 347 | 0.27 | Why? |
| Mitral Valve Prolapse | 1 | 2014 | 24 | 0.27 | Why? |
| Immune System Diseases | 1 | 2018 | 410 | 0.27 | Why? |
| Leukemia | 1 | 2019 | 598 | 0.26 | Why? |
| Wearable Electronic Devices | 2 | 2021 | 694 | 0.26 | Why? |
| Pacemaker, Artificial | 1 | 2018 | 431 | 0.26 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 436 | 0.26 | Why? |
| Platelet Aggregation Inhibitors | 3 | 2018 | 1671 | 0.26 | Why? |
| Alzheimer Disease | 2 | 2018 | 1020 | 0.26 | Why? |
| Heart Valve Diseases | 1 | 2017 | 355 | 0.25 | Why? |
| Echocardiography | 2 | 2019 | 3661 | 0.24 | Why? |
| Air Pollution | 4 | 2021 | 3504 | 0.23 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.23 | Why? |
| Defibrillators, Implantable | 1 | 2018 | 624 | 0.23 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.22 | Why? |
| Aortic Valve | 1 | 2017 | 664 | 0.22 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 1510 | 0.22 | Why? |
| Multiple Myeloma | 2 | 2017 | 1064 | 0.21 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1014 | 0.21 | Why? |
| Electronic Health Records | 2 | 2018 | 3492 | 0.21 | Why? |
| Heart Ventricles | 1 | 2019 | 1139 | 0.21 | Why? |
| Dyslipidemias | 1 | 2017 | 791 | 0.21 | Why? |
| Lipids | 1 | 2017 | 1079 | 0.20 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.20 | Why? |
| Cardiomyopathies | 1 | 2019 | 997 | 0.20 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2020 | 3892 | 0.19 | Why? |
| Magnetic Resonance Imaging, Cine | 2 | 2021 | 669 | 0.19 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.19 | Why? |
| Aortic Valve Stenosis | 1 | 2017 | 741 | 0.19 | Why? |
| Ohio | 2 | 2018 | 639 | 0.18 | Why? |
| Registries | 4 | 2021 | 12327 | 0.17 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 5277 | 0.17 | Why? |
| Genes, Mitochondrial | 1 | 2017 | 14 | 0.17 | Why? |
| Echocardiography, Doppler, Color | 1 | 2018 | 114 | 0.17 | Why? |
| Sweden | 3 | 2019 | 1969 | 0.17 | Why? |
| Exercise Test | 1 | 2014 | 911 | 0.17 | Why? |
| GRB7 Adaptor Protein | 1 | 2005 | 2 | 0.16 | Why? |
| Workplace | 1 | 2019 | 2075 | 0.16 | Why? |
| Seminoma | 1 | 2005 | 16 | 0.16 | Why? |
| Bundle-Branch Block | 1 | 2017 | 127 | 0.16 | Why? |
| Myocarditis | 2 | 2021 | 2731 | 0.14 | Why? |
| Models, Statistical | 3 | 2021 | 5312 | 0.14 | Why? |
| Cardiac Resynchronization Therapy | 1 | 2017 | 191 | 0.14 | Why? |
| Testicular Neoplasms | 1 | 2005 | 91 | 0.14 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2005 | 179 | 0.14 | Why? |
| Echocardiography, Transesophageal | 1 | 2018 | 447 | 0.14 | Why? |
| Heart Conduction System | 1 | 2017 | 266 | 0.13 | Why? |
| Follow-Up Studies | 8 | 2019 | 17020 | 0.13 | Why? |
| Natural Language Processing | 1 | 2018 | 436 | 0.13 | Why? |
| Proto-Oncogene Proteins | 1 | 2005 | 340 | 0.13 | Why? |
| Aged | 21 | 2021 | 215776 | 0.13 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.13 | Why? |
| Athletes | 1 | 2021 | 1047 | 0.13 | Why? |
| Aged, 80 and over | 12 | 2021 | 88759 | 0.12 | Why? |
| Global Health | 3 | 2021 | 13911 | 0.12 | Why? |
| Occupational Health | 1 | 2019 | 3965 | 0.12 | Why? |
| Information Storage and Retrieval | 1 | 2018 | 644 | 0.12 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.12 | Why? |
| Hemorrhage | 3 | 2018 | 3013 | 0.11 | Why? |
| Waiting Lists | 1 | 2020 | 1388 | 0.11 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.11 | Why? |
| Simvastatin | 1 | 2011 | 63 | 0.11 | Why? |
| National Health Programs | 1 | 2018 | 807 | 0.11 | Why? |
| Male | 25 | 2021 | 367725 | 0.11 | Why? |
| Female | 25 | 2021 | 380317 | 0.11 | Why? |
| Ventilators, Mechanical | 2 | 2020 | 2193 | 0.11 | Why? |
| Mass Screening | 2 | 2021 | 8005 | 0.11 | Why? |
| Water | 1 | 2006 | 765 | 0.11 | Why? |
| Informal Sector | 1 | 2019 | 4 | 0.10 | Why? |
| Time Factors | 5 | 2019 | 31397 | 0.10 | Why? |
| Databases, Factual | 2 | 2019 | 6248 | 0.10 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.10 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.10 | Why? |
| Humans | 38 | 2021 | 930598 | 0.10 | Why? |
| Risk Assessment | 6 | 2021 | 25439 | 0.10 | Why? |
| Neurogranin | 1 | 2018 | 18 | 0.10 | Why? |
| Leukemia, Hairy Cell | 1 | 2019 | 50 | 0.09 | Why? |
| Hypolipidemic Agents | 2 | 2017 | 208 | 0.09 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.09 | Why? |
| Cardiology | 2 | 2021 | 2873 | 0.09 | Why? |
| Chitinase-3-Like Protein 1 | 1 | 2018 | 28 | 0.09 | Why? |
| United States | 10 | 2021 | 46150 | 0.09 | Why? |
| Double-Blind Method | 4 | 2018 | 5988 | 0.09 | Why? |
| Risk Factors | 6 | 2019 | 71621 | 0.09 | Why? |
| Treatment Failure | 3 | 2018 | 2106 | 0.09 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.09 | Why? |
| Sarcoma, Kaposi | 1 | 2019 | 97 | 0.09 | Why? |
| Independent Living | 3 | 2018 | 842 | 0.09 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.09 | Why? |
| Medicine, Traditional | 1 | 2019 | 189 | 0.09 | Why? |
| Retrospective Studies | 7 | 2020 | 105322 | 0.08 | Why? |
| Poverty | 1 | 2019 | 2302 | 0.08 | Why? |
| Neurofilament Proteins | 1 | 2018 | 202 | 0.08 | Why? |
| Disease Transmission, Infectious | 2 | 2021 | 9044 | 0.08 | Why? |
| Cholesterol, LDL | 1 | 2011 | 499 | 0.08 | Why? |
| Administration, Oral | 3 | 2018 | 2340 | 0.08 | Why? |
| Ergonomics | 1 | 2019 | 182 | 0.08 | Why? |
| Amyloid beta-Peptides | 1 | 2018 | 185 | 0.08 | Why? |
| Air Pollutants | 2 | 2021 | 3110 | 0.08 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.08 | Why? |
| Health Status | 1 | 2019 | 3259 | 0.08 | Why? |
| Azetidines | 1 | 2011 | 722 | 0.07 | Why? |
| Incidence | 3 | 2019 | 25622 | 0.07 | Why? |
| Reoperation | 1 | 2017 | 544 | 0.07 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.07 | Why? |
| Mortality | 2 | 2018 | 7132 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Belgium | 1 | 2020 | 2064 | 0.06 | Why? |
| Algorithms | 1 | 2021 | 7346 | 0.06 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 526 | 0.06 | Why? |
| Neuropsychological Tests | 1 | 2018 | 954 | 0.06 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.06 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.06 | Why? |
| Patient Admission | 1 | 2019 | 5250 | 0.06 | Why? |
| Cognitive Dysfunction | 2 | 2018 | 1389 | 0.06 | Why? |
| False Positive Reactions | 1 | 2017 | 1338 | 0.06 | Why? |
| Adult | 11 | 2021 | 244371 | 0.06 | Why? |
| Dose-Response Relationship, Drug | 2 | 2017 | 3776 | 0.06 | Why? |
| Psychiatric Status Rating Scales | 1 | 2018 | 1340 | 0.06 | Why? |
| Length of Stay | 1 | 2019 | 11042 | 0.06 | Why? |
| Cause of Death | 2 | 2020 | 4823 | 0.06 | Why? |
| Geriatric Assessment | 1 | 2020 | 1372 | 0.06 | Why? |
| Time | 1 | 2014 | 631 | 0.05 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 877 | 0.05 | Why? |
| Australia | 3 | 2018 | 6306 | 0.05 | Why? |
| Reference Values | 2 | 2011 | 795 | 0.05 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.05 | Why? |
| Homes for the Aged | 1 | 2020 | 1071 | 0.05 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.05 | Why? |
| South Africa | 1 | 2019 | 3326 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.05 | Why? |
| Heart Failure | 1 | 2020 | 6638 | 0.05 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.04 | Why? |
| Environmental Health | 1 | 2021 | 203 | 0.04 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.04 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2021 | 867 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Norway | 1 | 2021 | 1004 | 0.04 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.04 | Why? |
| Oxidative Phosphorylation | 1 | 2017 | 120 | 0.04 | Why? |
| Models, Theoretical | 1 | 2006 | 6659 | 0.04 | Why? |
| Water Movements | 1 | 2006 | 9 | 0.04 | Why? |
| Renal Insufficiency, Chronic | 1 | 2011 | 2654 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2021 | 15421 | 0.04 | Why? |
| Water Pollutants | 1 | 2006 | 24 | 0.04 | Why? |
| ras Proteins | 1 | 2005 | 37 | 0.04 | Why? |
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 59 | 0.04 | Why? |
| DNA, Neoplasm | 1 | 2005 | 56 | 0.04 | Why? |
| Risk | 1 | 2018 | 5288 | 0.04 | Why? |
| Porosity | 1 | 2006 | 185 | 0.04 | Why? |
| Proto-Oncogene Proteins p21(ras) | 1 | 2005 | 100 | 0.04 | Why? |
| United Kingdom | 3 | 2021 | 18046 | 0.04 | Why? |
| Kidney Diseases | 1 | 2007 | 1434 | 0.04 | Why? |
| Mutation | 1 | 2005 | 12376 | 0.04 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.04 | Why? |
| Skin Neoplasms | 1 | 2019 | 1679 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Solubility | 1 | 2006 | 382 | 0.04 | Why? |
| Neoplasms | 2 | 2020 | 17251 | 0.03 | Why? |
| Receptor, ErbB-2 | 1 | 2005 | 267 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2014 | 4260 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| DNA Mutational Analysis | 1 | 2005 | 581 | 0.03 | Why? |
| Water Supply | 1 | 2006 | 294 | 0.03 | Why? |
| Nursing Homes | 1 | 2020 | 4155 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.03 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.03 | Why? |
| Netherlands | 1 | 2021 | 3533 | 0.03 | Why? |
| Thermodynamics | 1 | 2006 | 873 | 0.03 | Why? |
| Ezetimibe | 1 | 2011 | 50 | 0.03 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.03 | Why? |
| Proportional Hazards Models | 1 | 2014 | 6543 | 0.03 | Why? |
| Chronic Disease | 2 | 2021 | 5139 | 0.03 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2017 | 1326 | 0.03 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.02 | Why? |
| Oxidative Stress | 1 | 2021 | 2050 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Kidney Function Tests | 1 | 2011 | 520 | 0.02 | Why? |
| Confidence Intervals | 1 | 2011 | 744 | 0.02 | Why? |
| Particulate Matter | 1 | 2021 | 3249 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2014 | 9537 | 0.02 | Why? |
| England | 1 | 2020 | 5116 | 0.02 | Why? |
| Acute Disease | 1 | 2021 | 6029 | 0.02 | Why? |
| Annual Reports as Topic | 1 | 2007 | 13 | 0.02 | Why? |
| Disabled Persons | 1 | 2018 | 1152 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Dementia | 1 | 2018 | 1861 | 0.02 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Societies, Medical | 1 | 2021 | 6907 | 0.02 | Why? |
| Drug Administration Schedule | 1 | 2011 | 2324 | 0.02 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Child | 2 | 2018 | 70012 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Forecasting | 1 | 2006 | 4492 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2005 | 6740 | 0.01 | Why? |
| Animals | 1 | 2019 | 78931 | 0.01 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.01 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Renal Dialysis | 1 | 2011 | 4358 | 0.01 | Why? |
| China | 1 | 2021 | 50654 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Kidney Failure, Chronic | 1 | 2007 | 3222 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Kidney Transplantation | 1 | 2007 | 5397 | 0.00 | Why? |